1 terminated. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Polypoidal Choroidal Vasculopathy: new trials by email Literature Review of Polypoidal Choroidal Vasculopathy trials Research Report on Polypoidal Choroidal Vasculopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose - Polypoidal Choroidal Vasculopathy | Phase 2 / Phase 3 | Terminated | Sun Yat-sen University | 5 | 2018-08-01 | 2019-09-19 |
Choroid Diseases (1) · Choroidal Neovascularization (1) · Eye Diseases (1) · Metaplasia (1) · Neovascularization, Pathologic (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Uveal Diseases (1)
Ranibizumab (1)
China (1)
Lin Lu, MD, phD (1)
PMID 14557174, PMID 16897221, PMID 19726427, PMID 22426346, PMID 23352196, PMID 25646029